NEW YORK (GenomeWeb) – ERS Genomics said today that it has licensed its CRISPR-Cas9 genome editing technology to Lonza Pharma & Biotech for use in Lonza's bioproduction products and services and in induced pluripotent stem cells for research applications.
Financial terms of the agreement were not disclosed.
"We see tremendous potential for the use of gene editing to enhance the manufacturing of biologics and I expect Lonza will certainly be leading the way," ERS CEO Eric Rhodes said in a statement.
Ireland-based ERS was founded to provide access to foundational CRISPR-Cas9 IP held by Emmanuelle Charpentier. This CRISPR IP is also held by Jennifer Doudna and the University of California and is separate from genome editing patents held by the Broad Institute.
The company has signed several licensing deals for its technology in recent months, including with Thermo Fisher Scientific in September, with Axcelead Drug Discovery Partners and GenAhead Bio in October, and with DefiniGen in November.